 |
 |

Clinical Trials in HypertensionReply
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
In Reply: The meta-analysis that we conducted in 19971 included the available evidence from placebo-controlled trials of -blockers and diuretics. Dr Messerli and colleagues question whether the findings of Lindholm et al2 actually confirm ours. Regarding the placebo-controlled trials of -blockers, our findings agree with Figure 2A in Lindholm et al. For example, in both meta-analyses, -blockers compared with placebo were associated with a reduced risk of stroke but not coronary disease.1-2 The 1997 JNC 6 recommendations3 were appropriately evidence-based, using the clinical trial findings of an actual health benefit as evidence.
The 1997 meta-analysis1 also drew attention to the importance of low-dose diuretics, which were associated with decreased risks of stroke, coronary disease, heart failure, and total mortality. Our more recent 2003 meta-analysis4 provided additional evidence about the efficacy and safety of low-dose diuretic therapy, which led us to conclude that low-dose diuretics are the most effective first-line treatment . . . [Full Text of this Article]
Bruce M. Psaty, MD, PhD
psaty@u.washington.edu Department of Medicine
Noel S. Weiss, MD, DrPH, MPH
Department of Epidemiology University of Washington Seattle
Curt D. Furberg, MD, PhD
Wake Forest University School of Medicine Winston-Salem, NC
RELATED ARTICLES
Clinical Trials in Hypertension
Franz H. Messerli, Gareth Beevers, Stanley S. Franklin, and Thomas G. Pickering
JAMA. 2006;296(12):1463.
EXTRACT
| FULL TEXT
Clinical Trials in Hypertension
Simeon Pollack
JAMA. 2006;296(12):1464.
EXTRACT
| FULL TEXT
Recent Trials in Hypertension: Compelling Science or Commercial Speech?
Bruce M. Psaty, Noel S. Weiss, and Curt D. Furberg
JAMA. 2006;295(14):1704-1706.
EXTRACT
| FULL TEXT
|